396 related articles for article (PubMed ID: 30835621)
21. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
22. Improved Therapeutic Window in
Zhong H; Chen C; Tammali R; Breen S; Zhang J; Fazenbaker C; Kennedy M; Conway J; Higgs BW; Holoweckyj N; Raja R; Harper J; Pierce AJ; Herbst R; Tice DA
Mol Cancer Ther; 2019 Jan; 18(1):89-99. PubMed ID: 30352801
[TBL] [Abstract][Full Text] [Related]
23. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
Kumar A; Mao S; Dimasi N; Gao C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
[TBL] [Abstract][Full Text] [Related]
24. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
[TBL] [Abstract][Full Text] [Related]
25. Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.
Pei Z; Chen C; Chen J; Cruz-Chuh JD; Delarosa R; Deng Y; Fourie-O'Donohue A; Figueroa I; Guo J; Jin W; Khojasteh SC; Kozak KR; Latifi B; Lee J; Li G; Lin E; Liu L; Lu J; Martin S; Ng C; Nguyen T; Ohri R; Lewis Phillips G; Pillow TH; Rowntree RK; Stagg NJ; Stokoe D; Ulufatu S; Verma VA; Wai J; Wang J; Xu K; Xu Z; Yao H; Yu SF; Zhang D; Dragovich PS
Mol Pharm; 2018 Sep; 15(9):3979-3996. PubMed ID: 30040421
[TBL] [Abstract][Full Text] [Related]
26. Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Clardy SM; Uttard A; Du B; Catcott KC; Lancaster KL; Ditty E; Sadowsky J; Zurita J; Malli N; Qin L; Bradley SP; Avocetien K; Carter T; Kim D; Nazzaro M; Xu L; Pillow TH; Zacharias NT; Lewis GD; Rowntree RK; Iyengar R; Lee DH; Damelin M; Toader D; Lowinger TB
Mol Cancer Ther; 2024 Jan; 23(1):84-91. PubMed ID: 37774393
[TBL] [Abstract][Full Text] [Related]
27. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Graziani EI; Sung M; Ma D; Narayanan B; Marquette K; Puthenveetil S; Tumey LN; Bikker J; Casavant J; Bennett EM; Charati MB; Golas J; Hosselet C; Rohde CM; Hu G; Guffroy M; Falahatpisheh H; Finkelstein M; Clark T; Barletta F; Tchistiakova L; Lucas J; Rosfjord E; Loganzo F; O'Donnell CJ; Gerber HP; Sapra P
Mol Cancer Ther; 2020 Oct; 19(10):2068-2078. PubMed ID: 32747418
[TBL] [Abstract][Full Text] [Related]
28. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
[TBL] [Abstract][Full Text] [Related]
29. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers.
Gregson SJ; Barrett AM; Patel NV; Kang GD; Schiavone D; Sult E; Barry CS; Vijayakrishnan B; Adams LR; Masterson LA; D'Hooge F; Snaith M; Harper J; Hartley JA; Howard PW
Eur J Med Chem; 2019 Oct; 179():591-607. PubMed ID: 31279293
[TBL] [Abstract][Full Text] [Related]
31. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
32. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
33. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates.
Chowdari NS; Zhang Y; McDonald I; Johnson W; Langley DR; Sivaprakasam P; Mate R; Huynh T; Kotapati S; Deshpande M; Pan C; Menezes D; Wang Y; Rao C; Sarma G; Warrack BM; Rangan VS; Mei-Chen S; Cardarelli P; Deshpande S; Passmore D; Rampulla R; Mathur A; Borzilleri R; Rajpal A; Vite G; Gangwar S
J Med Chem; 2020 Nov; 63(22):13913-13950. PubMed ID: 33155811
[TBL] [Abstract][Full Text] [Related]
36. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
[TBL] [Abstract][Full Text] [Related]
37. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
38. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
39. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
[TBL] [Abstract][Full Text] [Related]
40. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
